Most Read Articles
5 days ago
Less focus must be given on pretreatment blood pressure (BP) levels, which rarely predict future untreated BP levels or rule out capacity to benefit from BP lowering in high cardiovascular risk patients, according to recent study. Focus must be directed instead on prompt, empirical treatment to maintain lower BP for individuals with high BP or high risk.
16 Nov 2018
Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.
15 Nov 2018
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Audrey Abella, 16 Nov 2018
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.

Cognitive impairment tied to poor antihypertensive medication adherence among elderly adults

16 Aug 2018
When is enough really enough for patients in light of the growing shift towards polypharmacy?

Cognitive impairment appears to be a risk factor for poor adherence to antihypertensive medication among elderly adults without dementia, a recent study has shown.

The study included 20,071 elderly hypertensive adults without a history of dementia (60 years; 54.3 percent female), of whom 16.4 percent (n=3,297) were poorly compliant with antihypertensive medication.

Multivariate logistic regression analysis showed that low cognitive function was associated with poor medication adherence, such that each increment in the Prescreening Korean Dementia Screening Questionnaire was associated with a significant drop in the likelihood of good adherence (adjusted odds ratio [OR], 0.980; 96 percent CI, 0.961–0.999; p=0.042).

The presence of comorbidities, such as stroke (adjusted OR, 1.351; 1.151–1.585; p<0.001), coronary heart disease (adjusted OR, 1.501; 1.330–1.694; p<0.001), diabetes (adjusted OR, 1.639; 1.492–1.800; p<0.001) and dyslipidaemia (adjusted OR, 1.533; 1.388–1.693; p<0.001), was associated with better medication adherence.

In contrast, being diagnosed with cancer appeared to increase the likelihood of poor adherence (adjusted OR, 0.802; 0.686–0.939; p=0.006).

Sex (female vs male: adjusted OR, 0.929; 0.860–1.004; p=0.063) and scores in the Geriatric Depression Scale (adjusted OR, 0.988; 0.947–1.031; p=0.584) were unrelated to the risk of poor antihypertensive medication adherence.

“[C]linicians involved with geriatric care should monitor patients’ cognitive function and medication adherence. If a patient shows cognitive impairment, clinicians need to educate both the patient and caregiver about the importance of proper adherence. Clinicians should also consider interventions that optimize the cognitive function of elderly patients,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Less focus must be given on pretreatment blood pressure (BP) levels, which rarely predict future untreated BP levels or rule out capacity to benefit from BP lowering in high cardiovascular risk patients, according to recent study. Focus must be directed instead on prompt, empirical treatment to maintain lower BP for individuals with high BP or high risk.
16 Nov 2018
Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.
15 Nov 2018
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Audrey Abella, 16 Nov 2018
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.